Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605536 | 1.00 | ROCK2 (0.37) | ROCK2SIGMAR1RORCHRH3LIPE | |
| SCHEMBL5606762 | 1.00 | ROCK2 (0.37) | ROCK2SIGMAR1RORCHRH3LIPE | |
| SCHEMBL5605532 | 1.00 | ROCK2 (0.37) | ROCK2SIGMAR1RORCHRH3LIPE | |
| SCHEMBL5610451 | 0.92 | ROCK2 (0.38) | ROCK2SIGMAR1LIPE | |
| SCHEMBL1738782 | 0.92 | ROCK2 (0.38) | ROCK2SIGMAR1LIPE | |
| SCHEMBL5606426 | 0.92 | ROCK2 (0.38) | ROCK2SIGMAR1LIPE | |
| SCHEMBL5606432 | 0.92 | ROCK2 (0.38) | ROCK2SIGMAR1LIPE | |
| SCHEMBL1738748 | 0.88 | SIGMAR1 (0.35) | ROCK2SIGMAR1LIPE | |
| SCHEMBL1740166 | 0.84 | FPR2 (0.36) | ROCK2SIGMAR1HRH3 | |
| SCHEMBL1738839 | 0.84 | FPR2 (0.36) | ROCK2SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | claimed |
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | claimed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2007026224-A2 | 5-HT1B ANTAGONIST COMPOSITION FOR DEPRESSION, ANXIETY AND COGNITION | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | claimed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090300-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026224-A2 | 5-HT1B ANTAGONIST COMPOSITION FOR DEPRESSION, ANXIETY AND COGNITION | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090300-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | ROCK2 4391/4885SIGMAR1 95/4885RORC 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.